Search research articles
Contact Us
Filters
Showing results (101-110 of 132) with videos related to
Page
of 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 24, 2003
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)
P Chollet, P Schöffski, K Weigang-Köhler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 1, 1994
Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma
C Cussac, E Mounetou, M Rapp, et al.
Oncology Research
|
March 25, 2006
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
C Abrial, M Leheurteur, A Cabrespine, et al.
Breast (Edinburgh, Scotland)
|
August 20, 2011
Late lines of treatment benefit survival in metastatic breast cancer in current practice?
E Planchat, C Abrial, E Thivat, et al.
Cancer
|
June 22, 1999
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy
F Lévi, R Zidani, S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 1, 1997
Clinical and pathological response to primary chemotherapy in operable breast cancer
P Chollet, S Charrier, E Brain, et al.
Medical Oncology (Northwood, London, England)
|
August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers
C Abrial, M A Mouret-Reynier, S Amat, et al.
Cancer Investigation
|
October 21, 2011
Prognostic value of initial tumor parameters after metastatic relapse
E Planchat, X Durando, C Abrial, et al.
Oncology
|
November 7, 2012
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors
E Thivat, I Van Praagh, A Belliere, et al.
Melanoma Research
|
February 8, 2000
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group
H Cure, P Souteyrand, R Ouabdesselam, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 132) with videos related to
Sort By:
Page
of 14
European Journal of Cancer (Oxford, England : 1990)
|
May 24, 2003
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)
P Chollet, P Schöffski, K Weigang-Köhler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 1, 1994
Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma
C Cussac, E Mounetou, M Rapp, et al.
Oncology Research
|
March 25, 2006
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
C Abrial, M Leheurteur, A Cabrespine, et al.
Breast (Edinburgh, Scotland)
|
August 20, 2011
Late lines of treatment benefit survival in metastatic breast cancer in current practice?
E Planchat, C Abrial, E Thivat, et al.
Cancer
|
June 22, 1999
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy
F Lévi, R Zidani, S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 1, 1997
Clinical and pathological response to primary chemotherapy in operable breast cancer
P Chollet, S Charrier, E Brain, et al.
Medical Oncology (Northwood, London, England)
|
August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers
C Abrial, M A Mouret-Reynier, S Amat, et al.
Cancer Investigation
|
October 21, 2011
Prognostic value of initial tumor parameters after metastatic relapse
E Planchat, X Durando, C Abrial, et al.
Oncology
|
November 7, 2012
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors
E Thivat, I Van Praagh, A Belliere, et al.
Melanoma Research
|
February 8, 2000
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group
H Cure, P Souteyrand, R Ouabdesselam, et al.
Page
of 14